ReAlta Life Sciences Names Ellen Lubman as Chief Business Officer

ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, has appointed Ellen Lubman, MBA as Chief Business Officer. In this role, Lubman will oversee business development, capital formation, and corporate strategy.

“Ellen is a highly respected executive with a strong track record of building partnerships, raising capital, and developing successful corporate strategies for biotech and pharmaceutical companies,” said David Marek, CEO of ReAlta. “Her deep strategic and transactional expertise strengthens our team, and she will play a key leadership role as we forge partnerships with pharmaceutical companies and investors alike to advance our transformative therapies for patients across numerous severe inflammatory diseases with high unmet need.”

Experience

Lubman brings broad experience across small to large-cap private and public biopharmaceutical companies, with a track record in strategic, transactional, and operational roles.

She joins ReAlta from Werewolf Therapeutics where she was Chief Business Officer, ushering the company through multiple financings, including an Initial Public Offering, as well as business development transactions. Prior to Werewolf, she was Chief Business Officer of Impel Pharmaceuticals and Vice President of External Science & Innovation at Allergan, where she was responsible for strategic expansion of the company’s pipeline of therapeutics in a variety of disease areas.

Lubman has held numerous other executive and leadership roles at Kadmon Pharmaceuticals, Bristol Myers Squibb, Celtic Pharma Management, L.P., Robertson Stephens Investment Bank, and Abbott Labs. She serves on the Board of Directors of Reunion Neuroscience and Cytovation ASA and is a Strategic Advisor to Two Bear Capital.

Lubman earned her M.B.A. from Stanford Graduate School of Business with a focus on Global Management and her B.A. in Biology from Rutgers College.